Exosomal MicroRNA-32-5p Induces Multidrug Resistance in Hepatocellular Carcinoma Via the PI3K/Akt Pathway

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2018 Mar 14

PMID 29530052

Citations 146

Authors

Xiao Fu

Mengjie Liu

Shengyang Qu

Jiequn Ma

Yamin Zhang

Tingting Shi

Hongqing Wen

Yujuan Yang

Shuhong Wang

Jing Wang

Kejun Nan

Yu Yao

Tao Tian

Affiliations

Soon will be listed here.

Abstract

Background: Multidrug resistance is the main obstacle for hepatocellular carcinoma (HCC) treatment. miR-32-5p is involved in HCC progression but its function in multidrug resistance is still unclear. Here we aim to find out the function of miR-32-5p in inducing multidrug resistance and its underlying mechanisms of transforming sensitive cell to resistant cell.

Methods: We detected the expression of miR-32-5p and PTEN in the multidrug-resistant cell line (Bel/5-FU) and the sensitive cell line (Bel7402), HCC and para-carcinoma liver tissues through real-time PCR. Dual-luciferase reporter assay verified PTEN is the target of miR-32-5p. Exosomes from sensitive and multidrug resistant cell line were obtained and confirmed through ultracentrifuge and Nano Analyzer. Gain- and loss-of-function experiments, rescue experiments, a PI3K/Akt pathway inhibitor, an exosome biogenesis inhibitor, and nude mice xenograft models were used to determine the underlying mechanisms of miR-32-5p and PTEN, as well as exosomal miR-32-5p in inducing multidrug resistance in vitro and in vivo.

Results: miR-32-5p was significantly elevated but PTEN was reduced in Bel/5-FU. An inverse correlation between miR-32-5p and PTEN was confirmed in HCC cell lines and patients; moreover, high expression of miR-32-5p and low expression of PTEN were positively associated with poor prognosis. Over-expression of miR-32-5p activated the PI3K/Akt pathway by suppressing PTEN and induced multidrug resistance via exosomes through promoting angiogenesis and epithelial-mesenchymal transition (EMT).

Conclusions: Our study demonstrated that the multidrug-resistant cell, Bel/5-FU delivers miR-32-5p to sensitive cell, Bel7402 by exosomes and activates the PI3K/Akt pathway to further induce multidrug resistance by modulating angiogenesis and EMT.

Citing Articles

Multi-stage mechanisms of tumor metastasis and therapeutic strategies.

Liu Z, Chen J, Ren Y, Liu S, Ba Y, Zuo A Signal Transduct Target Ther. 2024; 9(1):270.

PMID: 39389953 PMC: 11467208. DOI: 10.1038/s41392-024-01955-5.

MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities.

Mahboobnia K, Beveridge D, Yeoh G, Kabir T, Leedman P Int J Mol Sci. 2024; 25(17).

PMID: 39273339 PMC: 11395074. DOI: 10.3390/ijms25179393.

The Role of microRNAs in Hepatocellular Cancer: A Narrative Review Focused on Tumor Microenvironment and Drug Resistance.

Tavakoli Pirzaman A, Alishah A, Babajani B, Ebrahimi P, Sheikhi S, Moosaei F Technol Cancer Res Treat. 2024; 23:15330338241239188.

PMID: 38634139 PMC: 11025440. DOI: 10.1177/15330338241239188.

The underlying mechanism and targeted therapy strategy of miRNAs cross-regulating EMT process through multiple signaling pathways in hepatocellular carcinoma.

Chen J, He F, Peng H, Guo J Front Mol Biosci. 2024; 11:1378386.

PMID: 38584703 PMC: 10995332. DOI: 10.3389/fmolb.2024.1378386.

Research progress of exosomes in the angiogenesis of digestive system tumour.

Liu Y, Wu H, Sang Y, Chong W, Shang L, Li L Discov Oncol. 2024; 15(1):33.

PMID: 38341827 PMC: 10859358. DOI: 10.1007/s12672-024-00879-4.

References

Li B, Li J, Xu W, Guan X, Qin Y, Zhang L . Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. Oncotarget. 2014; 5(22):11576-87. PMC: 4294385. DOI: 10.18632/oncotarget.2596. View

Zhou W, Fu X, Zhang L, Zhang J, Huang X, Lu X . The AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cells. Cell Death Dis. 2013; 4:e847. PMC: 3824684. DOI: 10.1038/cddis.2013.375. View

Wei F, Ma C, Zhou T, Dong X, Luo Q, Geng L . Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p. Mol Cancer. 2017; 16(1):132. PMC: 5526308. DOI: 10.1186/s12943-017-0694-8. View

Shen H, Li L, Yang S, Wang D, Zhong S, Zhao J . MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway. Gene. 2016; 593(1):84-90. DOI: 10.1016/j.gene.2016.08.016. View

Yang S, Huang C, Li X, Yu M, He Y, Li J . miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013; 306:162-8. DOI: 10.1016/j.tox.2013.02.014. View

Wilson R, Espinosa-Diez C, Kanner N, Chatterjee N, Ruhl R, Hipfinger C . MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nat Commun. 2016; 7:13597. PMC: 5133658. DOI: 10.1038/ncomms13597. View

Meads M, Gatenby R, Dalton W . Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9(9):665-74. DOI: 10.1038/nrc2714. View

Giovannetti E, Funel N, Peters G, Del Chiaro M, Erozenci L, Vasile E . MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010; 70(11):4528-38. DOI: 10.1158/0008-5472.CAN-09-4467. View

Xiong B, Cheng Y, Ma L, Zhang C . MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. Int J Oncol. 2012; 42(1):219-28. DOI: 10.3892/ijo.2012.1707. View

10.

Hobert J, Eng C . PTEN hamartoma tumor syndrome: an overview. Genet Med. 2009; 11(10):687-94. DOI: 10.1097/GIM.0b013e3181ac9aea. View

11.

Ren P, Gong F, Zhang Y, Jiang J, Zhang H . MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN. Tumour Biol. 2015; 37(3):3215-25. DOI: 10.1007/s13277-015-4150-3. View

12.

Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti C . ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell. 2010; 17(4):319-32. PMC: 2881822. DOI: 10.1016/j.ccr.2010.02.030. View

13.

Dong Y, Richards J, Gupta R, Aung P, Emley A, Kluger Y . PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene. 2013; 33(38):4632-42. DOI: 10.1038/onc.2013.409. View

14.

Niu R, Zhang L, Xi G, Wei X, Yang Y, Shi Y . Up-regulation of Twist induces angiogenesis and correlates with metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2007; 26(3):385-94. View

15.

Bu X, Mahoney K, Freeman G . Learning from PD-1 Resistance: New Combination Strategies. Trends Mol Med. 2016; 22(6):448-451. PMC: 6833952. DOI: 10.1016/j.molmed.2016.04.008. View

16.

Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X . MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. 2017; 108(4):620-631. PMC: 5406601. DOI: 10.1111/cas.13177. View

17.

Ruan Z, Xu R, Lv Y, Tian T, Wang W, Guo H . PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib. Oncol Res. 2012; 20(2-3):113-21. DOI: 10.3727/096504012x13477145152995. View

18.

Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P . Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. 2013; 126(Pt 24):5553-65. DOI: 10.1242/jcs.128868. View

19.

Blackwell R, Foreman K, Gupta G . The Role of Cancer-Derived Exosomes in Tumorigenicity & Epithelial-to-Mesenchymal Transition. Cancers (Basel). 2017; 9(8). PMC: 5575608. DOI: 10.3390/cancers9080105. View

20.

Tian T, Nan K, Guo H, Wang W, Ruan Z, Wang S . PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol Rep. 2010; 23(6):1593-600. DOI: 10.3892/or_00000800. View